# DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Source: https://onco.cc/trials/nct05566795/  
OnCo record `nct05566795` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tovorafenib in glioma & glioblastoma, run by Day One Biopharmaceuticals, Inc., active and no longer recruiting.

## Summary

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) is a phase 3 interventional study registered as NCT05566795 by Day One Biopharmaceuticals, Inc., with 418 participants enrolled, started 2023-02-27 and due to reach its primary completion in 2027-06. Interventions recorded: Tovorafenib and Chemotherapeutic Agent.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05566795
- Phase: 3
- Setting: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
- Sponsor: Day One Biopharmaceuticals, Inc.
- Enrolled: 418

## Sources

- ClinicalTrials.gov NCT05566795: https://clinicaltrials.gov/study/NCT05566795

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Tovorafenib](https://onco.cc/drugs/tovorafenib/)
- companies: [Day One Biopharmaceuticals](https://onco.cc/companies/day-one-biopharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct05566795.json